http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CO-5601024-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_757c3a30eee57315f364b0563b0ecea6 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P33-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-685 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-661 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P33-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-685 |
| filingDate | 2004-07-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e1d0a1dcd730212e15784ecc13a129e5 |
| publicationDate | 2006-01-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CO-5601024-A2 |
| titleOfInvention | USE OF ALQUILFOSFOCOLINAS FOR THE PREVENTIVE TREATMENT OF DISEASES CAUSED BY PROTOZOOS |
| abstract | 1.- The use of alkyl phosphocholines for the production of a medicament for the preventive treatment of protozoan diseases in humans. 2.- The use according to claim 1, in which the total daily doses in the range of 10 to 250 mg of active ingredient of alkylphosphocholine, are administered orally for a period from 2 weeks to 6 months, preferably for the duration of the risk of infection.3.- The use according to claims 1 and 2, characterized in that hexadecylphosphocholine (miltefosine) or octadecyl 1,1-dimethylpiperidinium-4-yl phosphate (periposine), is used for the production of a medicament for preventive treatment, in particular leishmaniasis in humans by oral administration and total daily doses in the range of 10 to 250 mg of active ingredient miltefosine or peripheosin, are administered orally for a period from 2 weeks to 6 months, preferably for the duration of the risk of infection. n.4.- The use according to claims 1 to 3, characterized in that the total daily dose is about 20 to about 150 mg active ingredient or perifosine miltefosine. |
| priorityDate | 2002-01-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 24.